Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14031768 | 0.79 | HTR1D (0.38) | CYP1A2CYP2D6ADRA2AADRA2BADRA2C | |
| SCHEMBL17026824 | 0.78 | ADRA2A (0.32) | ADRA2AADRA2BADRA2CADRA1DHTR1D | |
| SCHEMBL24415036 | 0.75 | CYP1A2 (0.34) | CYP1A2CYP2D6ADRA2AADRA2BADRA2C | |
| SCHEMBL10912802 | 0.71 | SRC (0.46) | — | |
| SCHEMBL25450371 | 0.69 | SIGMAR1 (0.33) | CYP1A2CYP2D6ADRA2AADRA2BADRA2C | |
| SCHEMBL14329032 | 0.68 | GABRA1 (0.41) | ADRA2AADRA2BADRA2CADRA1DHTR1D | |
| SCHEMBL14330930 | 0.68 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1DHTR1D | |
| SCHEMBL25632131 | 0.68 | CYP1A2 (0.33) | CYP1A2CYP2D6 | |
| SCHEMBL6421470 | 0.67 | MAPT (0.50) | — | |
| SCHEMBL4567538 | 0.66 | AR (0.43) | HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | MCL1, BCL2A1, BCL2L1 | CYP1A2 3283/4885CYP2D6 3403/4885ADRA2A 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.